TNFRSF10A antibody (AA 2-203)

Catalog No. ABIN5027281

Product Details anti-TNFRSF10A Antibody

Target: TNFRSF10A (Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A))

Binding Specificity: AA 2-203

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFRSF10A antibody is un-conjugated

Application: Western Blotting (WB)

Purification: Protein G Chromatography

Immunogen: A partial length recombinant human TRAIL/DR4 protein (amino acids 2-203) was used as an immunogen for this antibody.

Clone: ABM1B11

Isotype: IgG1 kappa

Application Details

Application Notes: WB: 2-4 μg/mL

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: PBS containing 0.05 % BSA, PH 7.4

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

Target Details for TNFRSF10A

Target: TNFRSF10A (Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A))

Alternative Name: TRAIL/DR4 (TNFRSF10A Products)

Synonyms: APO2 antibody, CD261 antibody, DR4 antibody, TRAILR-1 antibody, TRAILR1 antibody, TNFRSF10A antibody, TNF receptor superfamily member 10a antibody, tumor necrosis factor receptor superfamily member 26 antibody, tumor necrosis factor receptor superfamily, member 10a antibody, TNFRSF10A antibody, LOC510798 antibody

Background: Death receptor 4 (DR4) or TRAIL-R1, a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. DR4 expression is enhanced by DNA damage whether induced by ionizing radiation or by chemotherapeutic agents. On binding DR4, TRAIL induces cell death via caspase-dependent apoptosis. DR4 mediate oligomeric Abeta induction of extrinsic apoptotic pathways in human microvascular cerebral endothelial cells with activation of both caspase-8 and caspase-9. It is considered a promising molecular target for cancer therapy.

Molecular Weight: 50 kDa

Gene ID: 8797

UniProt: O00220

Pathways: Apoptosis, Positive Regulation of Endopeptidase Activity